Answer | Family Hx of hearing loss | LA12668-2 |
Answer | ICU stay > 5 days | LA12669-0 |
Answer | Hyperbilirubinemia with exchange transfusion | LA12673-2 |
Answer | Aminoglycoside administration for more than 5 days | LA12672-4 |
Answer | Asphyxia or Hypoxic Ischemic Encephalopathy | LA31563-2 |
Answer | ECMO | LA12670-8 |
Answer | In utero infection(s) such as herpes, rubella, syphilis, and toxoplasmosis | LA12674-0 |
Answer | In utero infection with cytomegalovirus (CMV) | LA31564-0 |
Answer | Mother + Zika and infant with no laboratory evidence and no clinical findings | LA31565-7 |
Answer | Mother + Zika and infant with laboratory evidence of Zika | LA31566-5 |
Answer | Craniofacial malformations: Other (e.g., ear dysplasia, oral facial clefting, white forelock, microphthalmia) | LA31852-9 |
Answer | Craniofacial malformations: microtia/atresia | LA31853-7 |
Answer | Congenital microcephaly, congenital or acquired hydrocephalus | LA31567-3 |
Answer | Temporal bone abnormalities | LA31568-1 |
Answer | Syndromes associated with atypical hearing thresholds | LA12676-5 |
Answer | Culture-positive infections associated with sensorineural hearing loss | LA12678-1 |
Answer | Significant head trauma | LA12679-9 |
Answer | Chemotherapy | LA6172-6 |
Answer | Caregiver concern about hearing | LA12667-4 |
Answer | None | LA137-2 |
answers-for | Hearing loss risk indicators [Identifier] | 58232-0 |
LONG_COMMON_NAME | en-US | NBS_hear_risk |
LOINC Version: 2.77